Biofrontera

Biofrontera AG engages in the research, development, and marketing of dermatological products. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biofrontera (NASDAQ: BFRI ) reported results for the first quarter of 2023. Biofrontera posted a loss per share of 28 cents.

BFRI Stock Earnings: Biofrontera Misses EPS, Revenue Estimates

Biofrontera AG (OTC:BFAGY) Q1 2022 Earnings Conference Call May 19, 2022 8:00 AM ET Company Participants Anke zur Mühlen - Corporate Communications & Investor Relations Ludwig Lutter - Chief Financial Officer Conference Call Participants Operator Dear ladies and gentlemen, welcome to the conference call of Biofrontera AG. At our customer's request, this conference will be recorded.

Biofrontera AG (BFAGY) Management on Q1 2022 Results - Earnings Call Transcript

Biofrontera Inc (NASDAQ: BFRI) shares are trading significantly higher Wednesday after the company announced it received U.S. Food and Drug Administration approval for its cGMP laboratory in Germany. The FDA has approved Biofrontera's German laboratory as a contract lab for batch.

Why Biofrontera Stock Is Surging Today

Biofrontera Inc. (BFRI) CEO Erica Monaco on Q4 2021 Results - Earnings Call Transcript

Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its American Depositary Shares (“ADS”) should be delisted from the Nasdaq Capital Market (“Nasdaq”) and its reporting obligations with the Securities and Exchange Commission (“SEC”) should be deregistered and terminated. The main purpose of the delisting is to reduce complexity in financial reporting and administrative costs.

Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs

Biofrontera Inc BFRI has provided an update on the patient recruitment for the Phase 3 study for superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (PDT) combined with BF-RhodoLED lamp in the U.S.  Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School. Click Here Now to Start your FREE Trial.

Why Are Biofrontera Shares Rising Today?

Biofrontera is eyeing significant growth opportunities for its FDA-approved skin disease photodynamic therapy drug "Ameluz". Updates regarding several ongoing clinical studies for expanded label indications can be a catalyst for the stock in 2022.

Is Biofrontera Stock A Buy Or Sell? Several Catalysts In 2022

Biofrontera Inc (NASDAQ:BFRI) is trading higher Tuesday on abnormally-high volume. The stock is seeing increased interest across social media platforms.

What's Going On With Biofrontera Shares Today?

The stock price of Biofrontera Inc (NASDAQ: BFRI) increased by over 40% during intraday trading today. This is why it happened.

Biofrontera Stock (BFRI): Why The Price Surged Today

Biofrontera (BFRI) stock is on the move today as traders take to Twitter (TWTR) to discuss the latest news surrounding the company. The post BFRI Stock Alert: The Social Media Chatter That Has Biofrontera Booming Today appeared first on InvestorPlace.

BFRI Stock Alert: The Social Media Chatter That Has Biofrontera Booming Today

Benchmark initiated coverage of Biofrontera Inc (NASDAQ:BFRI) with a Buy rating and $11 price target.  The Company specializes in medical dermatology, which recently came public in the U.S. as a carve-out from Germany's Biofrontera AG (NASDAQ:BFRA).

Biofrontera Shares Are Trading Higher After Benchmark Initiates Coverage

BFRI stock could rise on the company's treatment for actinic keratosis, which can lead to skin cancer, but it has hurdles to overcome first. The post Biofrontera Is Promising, But Could Be Limited by Competition and Volatility appeared first on InvestorPlace.

Biofrontera Is Promising, But Could Be Limited by Competition and Volatility

BFRI stock is an imperfect investment as Biofrontera isn't currently profitable, but a new patent could provide a significant revenue source. The post $20 Price Prediction Is Ambitious but Possible for Biofrontera appeared first on InvestorPlace.

$20 Price Prediction Is Ambitious but Possible for Biofrontera

The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biofrontera Inc (NASDAQ: BFRI) titled "Illumination for Photodynamic Therapy." The patent covers pain-reducing illumination protocol for photodynamic therapy (PDT).

Why Are Biofrontera Shares Surging Today?

Biofrontera (BFRI) stock is getting a boost on Thursday thanks to an update from the United States Patent and Trademark Office. The post BFRI Stock: The News That Has Biofrontera Shares Bounding Higher Today appeared first on InvestorPlace.

BFRI Stock: The News That Has Biofrontera Shares Bounding Higher Today

Biofrontera's (BFRI) CEO Erica Monaco on Q3 2021 Results - Earnings Call Transcript

Biofrontera (BFRI) stock is catching the eyes of investors on Wednesday following a bullish price prediction and new rating. The post BFRI Stock: 7 Things to Know About Biofrontera as Shares Rocket on $20 Price Prediction appeared first on InvestorPlace.

BFRI Stock: 7 Things to Know About Biofrontera as Shares Rocket on $20 Price Prediction

Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal disputes and other differences (see ad hoc announcement of September 11, 2020). Mr. Zours is an indirect major shareholder of Biofrontera AG, holding the shares in Biofrontera AG through various companies (hereinafter "Deutsche Balaton Group"). Another major shareholder is Maruho Deutschland GmbH, a subsidiary of Maruho Co. Ltd, Japan. At the upcoming Annual General Meeting of Biofrontera AG on December 14, 2021, new elections to the Supervisory Board will be held as scheduled. In the course of the mediation process, agreement was reached between the Deutsche Balaton Group and the incumbent Supervisory Board of Biofrontera AG on the candidates for the Supervisory Board. The incumbent Supervisory Board therefore intends to propose the following candidates for election at the Annual General Meeting:

Biofrontera AG announces mediation results

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q3 2021 Results - Earnings Call Transcript

Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021.

Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that two clinical studies for its prescription drug Ameluz® in the United States are being started with site initiations currently in progress, seven sites for the phase two study for the treatment of moderate- to- severe acne in adults as well as eight sites for the phase I safety study evaluating the safety of photodynamic therapy (PDT) with the simultaneous application of three tubes of Ameluz®.

Biofrontera AG announces initiation of clinical studies

Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2021 on Wednesday, November 17, 2021.

Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021

Leverkusen, Germany, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the approval of the new red-light source for photodynamic therapy (PDT), the BF-RhodoLED® XL, by the U.S. Food and Drug Administration (FDA). In accordance with FDA requirements, the approval was granted as a combination approval with our prescription drug Ameluz®, same as the approval with the predecessor model BF-RhodoLED®.

Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp

Leverkusen, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of September 2021.

Biofrontera reports preliminary approximate revenues for the month of September 2021

Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of August 2021.

News for Biofrontera Stock (BFRA)